Compliance · State rules

Office-use compounding in Louisiana

Not authorised for human office use; veterinary only

USPeptideRx EditorialLast reviewed: August 28, 2026

Louisiana’s only non-patient-specific compounding pathway runs to licensed veterinarians. Human compounding is permitted only pursuant to the receipt of a patient-specific prescription, and the veterinary channel carries the tightest numeric cap of any state reviewed here: 5% of dosage units, calculated monthly.

The governing rule

Louisiana’s office-use position is set by LAC Title 46, Part LIII, §2535. The text below is quoted verbatim; everything outside a quote block is our summary of it, and the two are kept visually separate on purpose.

LAC 46:LIII §2535(E) — "Veterinarian-Administered Compounds, also referred to as Pharmacy-Generated Drugs"

1. Upon receipt of a valid non-patient-specific medical order from a licensed veterinarian, the pharmacy may compound a preparation intended for administration to an animal patient by the veterinarian. 2. These preparations may not be distributed to any other third party by the pharmacy, nor may these preparations be further re-sold or distributed by the veterinarian... 3. This authorization is primarily intended to facilitate the preparation of medications needed for emergency use in a veterinary office practice... a. No Louisiana-licensed pharmacy may distribute any amount of practitioner-administered compounds in excess of 5 percent of the total amount of drug products dispensed and/or distributed from their pharmacy. b. The 5 percent limitation shall be calculated on a monthly basis and shall reference the number of dosage units. c. For those Louisiana-licensed pharmacies located outside Louisiana, the total amount distributed and/or dispensed shall reference the pharmacy’s total business within the state of Louisiana.

LAC 46:LIII §2535(E)(4) — the Board’s own federal-law warning

federal law or rule may not permit such activity by a licensed pharmacy... the board’s rules cannot legitimize an activity that is not permitted under federal law or rule... pharmacists engaging in this activity remain subject to the full force and effect of federal law enforcement.

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

Human compoundingHigh confidence: §2535(A)(2)(a)-(b) permit sterile and non-sterile compounding only "pursuant to the receipt of a patient-specific prescription," in compliance with FDCA § 503A and USP <797>/<795> respectively.
Quantity cap (veterinary)High confidence: 5% of the total dosage units dispensed and/or distributed, calculated monthly — the tightest of any state reviewed here, and unusual in being monthly rather than annual.
Non-resident pharmaciesHigh confidence: The 5% denominator is the pharmacy’s Louisiana business only.
Veterinary label elementsHigh confidence: §2535(G)(2) — pharmacy name, address and phone; veterinarian’s name; preparation name; strength and concentration; lot number; BUD; special storage requirements if applicable; pharmacy-assigned identification number; and the name or initials of the pharmacist performing the final check. No "for office use only" legend is required.
Sterile compounding approvalHigh confidence: §2535(B) — a pharmacy wishing to engage in sterile compounding must notify the Board and receive Board approval before beginning that practice, under a separate sterile compounding permit ($500 application, $500/yr renewal).
Sterile trainingHigh confidence: §2535(C) — an annual minimum of one hour of ACPE- or Board-approved CE on sterile drug preparation, plus documented initial and ongoing competency evaluation records.
ScopeHigh confidence: §2531(B) — the compounding rules apply to all compounded preparations, sterile and non-sterile, "regardless of the location of the patient, e.g., home, hospital, nursing home, hospice, or practitioner’s office."
Last changeHigh confidence: §2535 last amended at LR 49:66 (January 2023).The LAC Part LIII document reviewed is current through at least LR 52:686-689 (May 2026) and contains 2026 amendments to remote processing and remote access — none touching Subchapter C compounding.

Louisiana at a glance

Louisiana office-use compounding summary, reviewed 2026-08-28
Human office use	Not authorised — veterinary only
Sterile preparations	Board pre-approval required
Quantity cap	5% of dosage units, monthly
Mandatory label legend	None required
Board reporting	Pre-approval to begin sterile compounding
Last change	Jan 2023
Governing rule	LAC Title 46, Part LIII, §2535

Receiving 503B office stock in Louisiana

Louisiana stacks up to three credentials on the facility, and the main one does not come from the Board of Pharmacy. The Board issues no outsourcing-facility permit at all.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Louisiana asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inHigh confidence: A distributor licence from the Louisiana Board of Drug and Device Distributors — a separate agency from the Board of Pharmacy. R.S. 37:3462(6) defines distribution as sale or delivery "to a person other than the consumer or patient", which is what shipping to a prescriber is, and § 3462(12)(b) folds a compounder into "manufacturer". If the product is scheduled, add a Board of Pharmacy CDS licence: that facility category expressly includes "registered outsourcing facilities".Which sub-type the Board of Drug and Device Distributors assigns a 503B to is not established — its rules were last touched in 2017 and never got a 503B category. A Louisiana Department of Health Food and Drug Control Unit credential is a prerequisite to the CDS licence, and whether that reaches a facility physically outside Louisiana is unverified.
Does your practice need a permit?High confidence: None for non-controlled stock, and Louisiana says so affirmatively rather than by silence. LAC 46:XXXIV § 105.B.7 excludes acquisition by a health care entity for its own use from wholesale distribution, and §§ 105.A.8 and B.5 expressly contemplate legend drugs supplied "to licensed practitioners for office use".
Administer vs dispenseHigh confidence: Sharp, and statutory. LAC 46:XLV § 6503 defines administer as giving a drug for "immediate" application and dispense as giving it for "later" use, and § 6505.B provides that "no physician shall dispense any medication … unless he is currently registered with the board as a dispensing physician". In-office injection needs no registration; sending a vial home does.
Scheduled (controlled) stockHigh confidence: A separate CDS licence for every location. LAC 46:LIII § 2705.C.2: a practitioner’s licence "shall be valid in any location in Louisiana; however, the procurement and possession of controlled substances shall require a separate CDS license for each such location where controlled substances are possessed." A three-site practice needs three.

How to check a facility’s credential before you order is set out in how to place an office-use order.

The federal layer still applies

Federal law is a second, independent constraint — a state prohibition is not the only thing standing in the way. 21 U.S.C. § 353a conditions the federal compounding exemptions on a drug being compounded for an identified individual patient on receipt of a valid prescription order. A state rule cannot create a federal safe harbour, and several state rules say so in their own text. The separate federal pathway for non-patient-specific office stock is the 503B outsourcing facility — the differences are set out in 503A vs 503B.

For how Louisiana compares with the other states reviewed, see the state-by-state comparison.

What this page does not establish

One drafting ambiguity is worth knowing about. Section 2533 defines "Practitioner Administered Compounds" generically, with no species limit, while the only operative authorisation — § 2535(E) — is titled and scoped to veterinarians. This page does not read the generic definition as creating a human pathway, because § 2535(A)(2) affirmatively requires a patient-specific prescription for human compounding. How a Louisiana inspector would read the point is not something we can tell you.
The Louisiana statutory layer at R.S. 37:1161 and following is outside what this page covers. We checked the regulation against its own text and did not retrieve the statute.
The Board’s rulemaking-activity page rendered empty when we loaded it, so we cannot tell you either way whether Louisiana compounding rulemaking is pending.

Sources

Primary sources, fetched directly from the issuing body. No secondary summaries.